GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

OCUL · Sep 30, 2025

OCULAR THERAPEUTIX, INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001104659-25-105919General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

41.21% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-348.77% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-5.71% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

23.98% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

87.80% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-472.35% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

360.00% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

80.38% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 9.25%
Current: 41.21%
Delta: 31.96%

Cash Generation Increased

Previous: -410.42%
Current: -348.77%
Delta: 61.65%

Growth Increased

Previous: -18.14%
Current: -5.71%
Delta: 12.43%

Inventory Pressure Increased

Previous: 22.58%
Current: 23.98%
Delta: 1.40%

Margin Increased

Previous: 85.56%
Current: 87.80%
Delta: 2.25%

Profitability Increased

Previous: -502.57%
Current: -472.35%
Delta: 30.22%

R And D Intensity Decreased

Previous: 379.53%
Current: 360.00%
Delta: -19.53%

Sbc Intensity Increased

Previous: 71.91%
Current: 80.38%
Delta: 8.48%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · OCUL Fundamental State →Transitioned To · OCUL PROFITABILITY_INCREASED →Transitioned To · OCUL R_AND_D_INTENSITY_DECREASED →Transitioned To · OCUL SBC_INTENSITY_INCREASED →Transitioned To · OCUL Fundamental State →Transitioned To · OCUL CAPEX_INTENSITY_INCREASED →Transitioned To · OCUL CASH_GENERATION_INCREASED →Transitioned To · OCUL GROWTH_INCREASED →Transitioned To · OCUL INVENTORY_PRESSURE_INCREASED →Transitioned To · OCUL MARGIN_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.